Aphasias | Jotup

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Retrieved on:

星期一, 七月 26, 2021

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.

Key Points:

These imaging data were used for safety monitoring and longitudinal biomarker outcomes including quantification of neurodegeneration via MRI.
The OVERTURE study demonstrated that gamma frequency neuro-modulation led to a significant reduction in brain atrophy in AD patients.
Accelerated brain atrophy is associated with cognitive decline and loss of function in AD patients and is a driver of mortality and morbidity in Alzheimers disease progression.
Cognito Therapeutics is a clinical-stage neuro-physiology company developing a pipeline of disease-modifying digital therapeutics that have clinically demonstrated drug-like effects using gamma frequency neuromodulation to treat neurodegenerative disorders including Alzheimers disease.

Alzheimer's Disease (Central Nervous System) Drugs In Development, 2021 Market Research Report - ResearchAndMarkets.com

Retrieved on:

星期三, 七月 14, 2021

Health, Pharmaceutical, Branches of biology, Neuroscience, Biology, Abnormal psychology, Alzheimer's disease, Aphasias, Dementia, Steven M. Paul, Giovanna Mallucci

The "Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.
The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.
The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation

Retrieved on:

星期三, 七月 7, 2021

Psychiatry, Branches of biology, Neuroscience, Cognitive disorders, Psychiatric diagnosis, Learning disabilities, Aphasias, Dementia, Antipsychotic, Alzheimer's disease, Psychosis

Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, "We are very excited to begin our trial.

Key Points:

Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, "We are very excited to begin our trial.
Right now, the most common medical treatment for agitation associated with Alzheimer's is off-label use of antipsychotic drugs, which typically provide only marginal improvement, often with undesirable side effects.
AD is an irreversible neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning and judgment.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

A Car with a Mission: Racing to End Alzheimer's Seeks to Set New Fundraising Record for 2021

Retrieved on:

星期一, 六月 21, 2021

Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Alzheimer's disease, Neuroscience, Aphasias, Alzheimer's Association, Alzheimer's disease in the media

This year, Racing to End Alzheimer's founder, Phil Frengs, hopes to honor over 200 loved ones.

Key Points:

This year, Racing to End Alzheimer's founder, Phil Frengs, hopes to honor over 200 loved ones.
In 2017, Racing to End Alzheimer's began as a passion project for Frengs when his wife Mimi was diagnosed with early-onset Alzheimer's.
I started Racing to End Alzheimer's as a way to channel my emotions into something that might help others who were having similar experiences."
Learn more about Racing to End Alzheimer's or donate to remember your loved one on their website , r2endalz.org.

Alzheimer's Association Statement: Next Steps For New Alzheimer's Treatment

Retrieved on:

星期六, 六月 12, 2021

Branches of biology, Aphasias, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Medicine, Alzheimer's Association, Food and Drug Administration, Alzheimer's disease

Alzheimer's Association's research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA's decision.

Key Points:

Alzheimer's Association's research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA's decision.
Additionally, the FDA appropriately took into account the vast unmet need of the Alzheimer's community.
Aduhelm is certainly not a cure, but at long last it provides many with Alzheimer's disease and their families an effective treatment.
Our focus has and will continue to be access to this treatment for all likely to benefit.

FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease

Retrieved on:

星期二, 六月 8, 2021

Life sciences, Health sciences, Health, Abnormal psychology, Alzheimer's disease, Amyloidosis, Aphasias, Dementia, Biogen, Accelerated approval, Aducanumab, Latrepirdine

Continued approval for ADUHELM's indication as a treatment for Alzheimer's disease may be contingent upon verification of clinical benefit in confirmatory trial(s).

Key Points:

Continued approval for ADUHELM's indication as a treatment for Alzheimer's disease may be contingent upon verification of clinical benefit in confirmatory trial(s).
"This historic moment is the culmination of more than a decade of groundbreaking research in the complex field of Alzheimer's disease.
"We are very pleased to be able to open a new chapter in the history of Alzheimer's disease treatment with the approval of ADUHELM.
As part of the accelerated approval, Biogen will conduct a controlled trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease.

FDA: BrainSee Novel Software Is Breakthrough for Noninvasive Detection and Monitoring of Alzheimer's Disease at the Early Stage of Mild Cognitive Impairment

Retrieved on:

星期五, 五月 28, 2021

Branches of biology, Medicine, Psychiatric diagnosis, Clinical medicine, Cognitive disorders, Learning disabilities, Radiology, Alzheimer's disease, Aphasias, Magnetic resonance imaging, Prodrome, Radiation therapy

Using standard, non-invasive clinical brain MRI (no injection and no radiation), BrainSee detects Alzheimer's disease at the early prodromal stage, enabling timely medical interventions and care planning.

Key Points:

Using standard, non-invasive clinical brain MRI (no injection and no radiation), BrainSee detects Alzheimer's disease at the early prodromal stage, enabling timely medical interventions and care planning.
Such early detection or rule-out of Alzheimer's disease non-invasively and affordably is nonexistent in the clinical market today.
FDA has granted breakthrough status to BrainSee, a new AI-powered product by Darmiyan Inc. that detects Alzheimer's disease at the early prodromal stage.
Using standard, non-invasive clinical brain MRI (no injection and no radiation), BrainSee detects Alzheimer's disease at the early stage of mild cognitive impairment, enabling timely medical interventions and care planning.

Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on:

星期三, 五月 12, 2021

Branches of biology, Cognitive disorders, Dementia, Neuroscience, Psychiatric diagnosis, Learning disabilities, Aphasias, Frontotemporal lobar degeneration, Lewy body dementias, Lewy body, Alzheimer's disease, Neurodegeneration

b"BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.\nA live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events .

Key Points:

b"BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.\nA live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events .
The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.
Yumanity\xe2\x80\x99s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases.
Yumanity\xe2\x80\x99s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\xe2\x80\x99s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\xe2\x80\x99s disease.

BioVie Hosting Research & Development Day

Retrieved on:

星期三, 五月 12, 2021

Branches of biology, Clinical medicine, Medical specialties, Alzheimer's disease, Amyloidosis, Aphasias, Dementia, Psychiatric diagnosis, Insulin

It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.

Key Points:

It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.
BioVie recently announced its intention to acquire NE3107 from privately held NeurMedix Inc in a transaction expected to close in June.
In addition to Alzheimer\xe2\x80\x99s Disease, BioVie plans to enter clinical trials for the treatment of Parkinson\xe2\x80\x99s Disease and several oncological indications.
The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites.

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results

Retrieved on:

星期五, 四月 30, 2021

Branches of biology, Abnormal psychology, Alzheimer's disease, Aphasias, Dementia, Psychiatric diagnosis, Neuroscience, Psychiatry

This study will evaluate the safety and efficacy of our lead candidate, varoglutamstat, in patients with Alzheimer\'s Disease.

Key Points:

This study will evaluate the safety and efficacy of our lead candidate, varoglutamstat, in patients with Alzheimer\'s Disease.
We look forward to the continued implementation our growth strategy and to the additional opportunities gained by this corporate conversion.\nIn summary, 2020 was a pivotal year for Vivoryon.
I would therefore like to extend our sincere thanks to our shareholders for all their support throughout our transformation as well as to the whole Vivoryon team.
The reports are available on the company website ( https://www.vivoryon.com/investors-news/financial-information/ ).\n'